Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Skye BioscienceFRA:09R -16.54%19 Earnings Yield (Joel Greenblatt) % is -344.83% as of Jun. 2026. GuruFocus rates FRA:09R with a GF Score™ of 19/100. The stock has 2 warning signs investors should review. Among 1,343 Biotechnology companies, Skye Bioscience ranks better than 78.03% on this metric.
Skye Bioscience's Enterprise Value for the quarter that ended in Jun. 2026 was €10.40 Mil.
Skye Bioscience's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was €-43.38 Mil. Skye Bioscience's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2026 was -344.83%.
The historical rank and industry rank for Skye Bioscience's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
FRA:09R's Earnings Yield (Joel Greenblatt) % is not ranked *
in the Biotechnology industry.
Industry Median: -9.92 * Ranked among companies with meaningful Earnings Yield (Joel Greenblatt) % only.
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Skye Bioscience's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Skye Bioscience Earnings Yield (Joel Greenblatt) % Related Terms
Skye Bioscience Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Skye Bioscience's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Skye Bioscience's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Skye Bioscience Earnings Yield (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Skye Bioscience's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Skye Bioscience's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Skye Biosciences Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
Skye Bioscience's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-43.38 Mil.
What does a Earnings Yield (Joel Greenblatt) % of -344.83% mean?
Skye Bioscience (FRA:09R) has a Earnings Yield (Joel Greenblatt) % of -344.83% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Skye Bioscience and its competitors. According to the industry distribution chart, Skye Bioscience ranks #295 out of 1343 companies in the Biotechnology industry, placing it in the top 22%.
Is Skye Bioscience's Earnings Yield (Joel Greenblatt) % too high?
Skye Bioscience's current Earnings Yield (Joel Greenblatt) % is -344.83%. Based on the distribution chart, Skye Bioscience ranks #295 out of 1343 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Skye Bioscience has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Skye Bioscience's Earnings Yield (Joel Greenblatt) % compare to ATOS and JSPR?
According to the Biotechnology industry distribution chart, Skye Bioscience ranks #295 out of 1343 companies for Earnings Yield (Joel Greenblatt) %. This places Skye Bioscience in the top 22% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Biotechnology company?
A good Earnings Yield (Joel Greenblatt) % depends on the Biotechnology industry context. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Skye Bioscience and its competitors. Skye Bioscience's current Earnings Yield (Joel Greenblatt) % is -344.83%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Skye Bioscience stock overvalued right now?
Skye Bioscience (FRA:09R) has a current Earnings Yield (Joel Greenblatt) % of -344.83%. The current Earnings Yield (Joel Greenblatt) % is -344.83%. Skye Bioscience's overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Skye Bioscience (FRA:09R), the current Earnings Yield (Joel Greenblatt) % is -344.83% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
19GF Score
Get the complete analysis for FRA:09R
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:09R has been successfully added to your 
